Related Experiment Video

Updated: Jul 5, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.1K

Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K/AKT/mTOR signaling pathway

Lei Ma1, Ke Huang1, Haibo Zhang2

  • 1Department of Animal Science and Biotechnology, Research Center for Horse Industry, Kyungpook National University, Sangju, Gyeongsangbuk-do 37224, Republic of Korea.

Journal of Cancer
|January 12, 2024
PubMed

Insights

Imatinib effectively inhibits oral squamous cell carcinoma (OSCC) proliferation and viability. This study reveals imatinib

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Oral squamous cell carcinoma (OSCC) is a significant oral cancer with high mortality due to invasion and metastasis.
  • Imatinib shows promise in treating various cancers, but its specific effects on OSCC require further investigation.

Purpose of the Study:

  • To investigate the anticancer effects of imatinib on OSCC cells.
  • To elucidate the underlying mechanisms of imatinib's action in OSCC.

Main Methods:

  • Cell Counting Kit-8 assay for cell viability.
  • Morphological analysis for proliferation.
  • Wound-healing and soft agar assays for migration and colony formation.
  • Flow cytometry for apoptosis analysis.
  • Western blot to confirm molecular mechanisms.

Main Results:

  • Imatinib significantly inhibited OSCC cell proliferation and viability in a dose- and time-dependent manner.
  • Imatinib suppressed OSCC cell migration and colony formation.
  • Imatinib induced apoptosis by modulating p53, Bax, PARP, and Bcl-2 expression.
  • Imatinib inhibited the PI3K/AKT/mTOR signaling pathway.

Conclusions:

  • Imatinib demonstrates potent anticancer effects against OSCC cells.
  • Imatinib induces apoptosis and inhibits proliferation, migration, and colony formation in OSCC.
  • Imatinib holds potential as a therapeutic agent for oral cancer treatment.
Keywords:
PI3K/AKT/mTOR signaling pathwayimatiniboral squamous cell carcinomaproliferationviability

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K